DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/d990a7/product_profiles) has announced the addition of the "Product Profiles: Targeted Cancer Therapies - Trend towards personalized medicine will lead to market fragmentation" report to their offering.
The targeted therapies class boasts several of the top-selling anticancer brands, and has fueled most of the recent rapid growth of the oncology market as a whole. In the next decade, several blockbuster targeted therapies will undergo patent expiries and the market will become more fragmented as new targeted therapies are developed for niche populations.
Highlights
As a growing number of companies strive to develop targeted cancer therapies, competition will inevitably become more intense as more agents in this class reach the market. In addition, increasing pharmacoeconomic pressures will dampen sales growth of drugs in this market as they tend to command a high price. In recent years an improved understanding of the heterogeneity of cancer tumors and their molecular pathogenesis has led to the development of targeted therapies designed to treat niche subsets of patients with specific genetic mutations. The co-development of companion diagnostics that can identify the patients that will most benefit from cancer treatment will become increasingly important for developers seeking approval of targeted therapies and the treatment of cancer will become more personalized
MARKETED PRODUCT PROFILES:
- Adcetris (brentuximab vedotin; Seattle Genetics/Takeda)
- Afinitor (everolimus; Novartis)
- Arzerra (ofatumumab; Genmab/GlaxoSmithKline)
- Avastin (bevacizumab; Genentech/Roche/Chugai)
- Caprelsa (vandetanib; AstraZeneca)
- Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)
- Gleevec (imatinib; Novartis)
- Herceptin (trastuzumab; Roche/Chugai)
- Iressa (gefitinib; AstraZeneca)
- Istodax (romidepsin; Celgene)
- Nexavar (sorafenib; Bayer Schering/Onyx)
- Revlimid (lenalidomide; Celgene)
- Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)
- Sprycel (dasatinib; Bristol-Myers Squibb)
- Sutent (sunitinib; Pfizer)
- Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche)
- Tasigna (nilotinib; Novartis)
- Thalomid (thalidomide; Celgene)
- Torisel (temsirolimus; Pfizer)
- Tykerb (lapatinib; GlaxoSmithKline)
- Vectibix (panitumumab; Amgen)
- Velcade (bortezomib; Takeda
For more information visit http://www.researchandmarkets.com/research/d990a7/product_profiles
Source: Datamonitor